Company Profile
Protara Therapeutics Stock Price, News & Catalysts
- Ticker:
- TARA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.70 USD (+2.21%)
Close
Last updated: September 17, 2026
244M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, TARA closed up 2.21% at $3.70. No new same-company headline was identified in the current news window.
Company overview
Cancer and Rare-Disease Company
Protara Therapeutics develops therapies for cancer and rare diseases, with programs spanning cell-based immunopotentiation and phospholipid substrate replacement.
Bladder Cancer
The ADVANCED program evaluates intravesical TARA-002 in high-grade non-muscle-invasive bladder cancer across BCG-unresponsive, BCG-naïve, and BCG-exposed populations.
Lymphatic Malformations
The pivotal Phase 2 STARBORN-1 study evaluates intralesional TARA-002 in pediatric patients with macrocystic and mixed cystic lymphatic malformations.
IV Choline Chloride
IV Choline Chloride is an investigational phospholipid substrate replacement for patients on long-term parenteral support who cannot meet their choline needs through oral or enteral nutrition.
Future catalysts
- Completion of enrollment in the BCG-unresponsive cohort of the ADVANCED-2 study in the fourth quarter of 2026.
- Completion of enrollment and an updated analysis from the STARBORN-1 study in the fourth quarter of 2026.
- Interim results from the registrational Phase 3 THRIVE-3 study of IV Choline Chloride in the fourth quarter of 2026.
- Submission of a BLA for TARA-002 in lymphatic malformations in the second half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Protara Therapeutics (TARA)?
Protara Therapeutics (TARA) most recently closed at 3.70 USD, a +2.21% move versus the previous session.
What is the market cap of Protara Therapeutics (TARA)?
Protara Therapeutics currently has a market capitalization of 244M USD on BioPharmSignal.
What does Protara Therapeutics do?
Cancer and Rare-Disease Company Protara Therapeutics develops therapies for cancer and rare diseases, with programs spanning cell-based immunopotentiation and phospholipid substrate replacement. Bladder Cancer The ADVANCED program evaluates intravesical TARA-002 in high-grade non-muscle-invasive bladder cancer across BCG-unresponsive, BCG-naïve, and...
On which exchange is TARA stock listed?
Protara Therapeutics (TARA) is associated with NASDAQ, United States, Biopharma.
What is TARA-002?
Submission of a BLA for TARA-002 in lymphatic malformations in the second half of 2027.
Which conditions is Protara Therapeutics targeting with TARA-002?
Protara Therapeutics is associated with cancer therapeutics, rare disease based on its company overview and current catalyst commentary.
How does Protara Therapeutics describe recent progress with TARA-002?
Submission of a BLA for TARA-002 in lymphatic malformations in the second half of 2027.
What is STARBORN-1?
Lymphatic Malformations The pivotal Phase 2 STARBORN-1 study evaluates intralesional TARA-002 in pediatric patients with macrocystic and mixed cystic lymphatic malformations.